Literature DB >> 22542819

Body mass index, coronary artery calcification, and kidney function decline in stage 3 to 5 chronic kidney disease patients.

Jocelyn S Garland1, Rachel M Holden, Wilma M Hopman, Sudeep S Gill, Robert L Nolan, A Ross Morton.   

Abstract

OBJECTIVE: To determine whether body mass index (BMI) and coronary artery calcification (CAC) are risk factors for kidney function decline in predialysis chronic kidney disease (CKD) patients.
DESIGN: Prospective cohort study of 125 stage 3 to 5 predialysis CKD patients. SUBJECTS AND
SETTING: CKD patients receiving care in Kingston, Ontario, Canada.
METHODS: BMI, CAC, and kidney function were measured at baseline. CAC was measured by multislice computed tomography scan. Kidney function was determined by the 4-variable reexpressed Modification of Diet in Renal Disease Study equation. At study end, kidney function decline among patients was compared according to baseline BMI and CAC. MAIN OUTCOME: Kidney function decline was defined as a 1-year decline in estimated glomerular filtration rate (eGFR) of ≥ 5%.
RESULTS: Individuals with a decline in eGFR of ≥ 5% at 1 year had higher baseline BMI (33.5 ± 8.3 vs. 28.4 ± 4.9 kg/m(2); P = .0001) and higher baseline median CAC scores (239 vs. 25 Agatston units; P = .01) compared with subjects without such a decline. BMI (r = 0.35; P < .0001) and logarithmically transformed CAC score (r = 0.22; P = .01) correlated with an eGFR decline of ≥ 5%. Both crude and adjusted logistic regression analyses showed escalating CAC (with CAC reported in quintiles and CAC score = 0 Agatston unit as the reference group) was associated with an increased risk of eGFR decline of ≥ 5%.
CONCLUSIONS: CAC and BMI were associated with kidney function decline over 1 year. The risk of kidney function decline was greater in those with increasing burden of CAC, which remained robust in the adjusted analysis accounting for the risk factors for CKD progression. Larger studies will be required for independent validation of the associations of BMI, CAC, and kidney function decline, and to investigate whether obesity and CAC treatment strategies are efficacious in attenuating kidney function decline in predialysis CKD patients.
Copyright © 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22542819     DOI: 10.1053/j.jrn.2011.12.008

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  7 in total

Review 1.  Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD.

Authors:  Gates Colbert; Nishank Jain; James A de Lemos; S Susan Hedayati
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-17       Impact factor: 8.237

2.  Patency and Complications of Translumbar Dialysis Catheters.

Authors:  Fanna Liu; Stacy Bennett; Susana Arrigain; Jesse Schold; Robert Heyka; Gordon McLennan; Sankar D Navaneethan
Journal:  Semin Dial       Date:  2015-03-20       Impact factor: 3.455

3.  Coronary Artery Calcification Score and the Progression of Chronic Kidney Disease.

Authors:  Hae-Ryong Yun; Young Su Joo; Hyung Woo Kim; Jung Tak Park; Tae Ik Chang; Nak-Hoon Son; Tae-Hyun Yoo; Shin-Wook Kang; Suah Sung; Kyu-Beck Lee; Joongyub Lee; Kook-Hwan Oh; Seung Hyeok Han
Journal:  J Am Soc Nephrol       Date:  2022-06-02       Impact factor: 14.978

4.  Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease.

Authors:  Caitlyn Vlasschaert; Amy J M McNaughton; Michael Chong; Elina K Cook; Wilma Hopman; Bryan Kestenbaum; Cassianne Robinson-Cohen; Jocelyn Garland; Sarah M Moran; Guillaume Paré; Catherine M Clase; Mila Tang; Adeera Levin; Rachel Holden; Michael J Rauh; Matthew B Lanktree
Journal:  J Am Soc Nephrol       Date:  2022-02-23       Impact factor: 14.978

Review 5.  Elevated body mass index as a risk factor for chronic kidney disease: current perspectives.

Authors:  Jocelyn S Garland
Journal:  Diabetes Metab Syndr Obes       Date:  2014-07-29       Impact factor: 3.168

6.  Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Authors:  Marwa A Sabe; Brian Claggett; Emmanuel A Burdmann; Akshay S Desai; Peter Ivanovich; Reshma Kewalramani; Eldrin F Lewis; John J V McMurray; Kurt A Olson; Patrick Parfrey; Scott D Solomon; Marc A Pfeffer
Journal:  J Am Heart Assoc       Date:  2016-04-23       Impact factor: 5.501

7.  Impact of primary aldosteronism on renal function in patients with type 2 diabetes.

Authors:  Sho Katsuragawa; Yuya Tsurutani; Tomoko Takiguchi; Jun Saito; Tetsuo Nishikawa
Journal:  J Diabetes Investig       Date:  2020-07-26       Impact factor: 4.232

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.